Artiva Biotherapeutics, Inc. (ARTV) Research

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Market snapshot

Symbol
ARTV
Price
$9.82
Day change
-1.21%
Market cap
$242.7M
P/E ratio
-2.78x
52-week range
1.47-14.53
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$37.50

Recent news

  • Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

    Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) are down on Friday as the company announced initial clinical data regarding its AlloNK (AB-101) in combination with rituximab for autoimmune diseases and a $300 million private placement.

Peer companies

  • Adverum Biotechnologies, Inc. (ADVM)
  • ALX Oncology Holdings Inc. (ALXO)
  • Connect Biopharma Holdings Limited (CNTB)
  • Precision BioSciences, Inc. (DTIL)
  • Fractyl Health, Inc. Common Stock (GUTS)
  • InflaRx N.V. (IFRX)
  • Metagenomi, Inc. Common Stock (MGX)
  • Sutro Biopharma, Inc. (STRO)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (124893 shares) on 2026-06-16
  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (15414 shares) on 2026-06-15
  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (391019 shares) on 2026-06-12
  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (548580 shares) on 2026-06-11
  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (103 shares) on 2026-06-10

Open Artiva Biotherapeutics, Inc. (ARTV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.